Design of a novel LOX-1 receptor antagonist mimicking the natural substrate

Biochemical and Biophysical Research Communications

Volumn 438, Issue 2, 2013, Pages 340-345

  Falconi, Mattia ^a   Ciccone, Sarah ^b   D'Arrigo, Paola ^c   Viani, Fiorenza ^d   Sorge, Roberto ^b   Novelli, Giuseppe ^b   Patrizi, Patrizia ^e   Desideri, Alessandro ^a   Biocca, Silvia ^b  

^a NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c POLITECNICO DI MILANO   (Italy)

^d CNR   (Italy)

^e Bio Genetix Srl   (Italy)

Author keywords

Atherosclerosis; Cell based assay; LOX 1 inhibitor; Molecular docking; Ox LDL; Oxidized phospholipids

Indexed keywords

LYSINE; PHOSPHOLIPID DERIVATIVE; PLAZPC; SOLVENT; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SYNTHESIS; ENZYME SUBSTRATE; HYDROPHOBICITY; MOLECULAR DOCKING; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN INTERACTION;

1,1′-DIOCTADECYL-3,3,3′,3′-TETRAMETHYLLINDOCARBOCYANINE PERCHLORATE; 1-HYDROXYBENZOTRIAZOLE; ATHEROSCLEROSIS; C-TYPE LECTIN-LIKE DOMAIN; CELL-BASED ASSAY; CTLD; DII; HOBT; LDL; LECTIN-LIKE OXIDIZED LOW-DENSITY LIPOPROTEIN RECEPTOR-1; LOW-DENSITY LIPOPROTEIN; LOX-1; LOX-1 INHIBITOR; MOLECULAR DOCKING; OX-LDL; OXIDIZED LOW-DENSITY LIPOPROTEIN; OXIDIZED PHOSPHOLIPIDS; SRB; SULFORHODAMINE B;

ANIMALS; ATHEROSCLEROSIS; CERCOPITHECUS AETHIOPS; COS CELLS; DNA; DRUG DESIGN; ENDOTHELIUM, VASCULAR; HUMANS; LIGANDS; LYSINE; MOLECULAR DOCKING SIMULATION; OXYGEN; PHOSPHOLIPIDS; PROTEIN BINDING; PROTEIN CONFORMATION; SCAVENGER RECEPTORS, CLASS E; SUBSTRATE SPECIFICITY;

EID: 84882591365     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.07.073     Document Type: Article

References (25)

1. Sawamura T., Kume N., Aoyama T., Moriwaki H., Hoshikawa H., Aiba Y., Tanaka T., Miwa S., Katsura Y., Kita T., Masaki T. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997, 386:73-77.
2. Chen M., Masaki T., Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol. Ther. 2002, 95:89-100.
3. Mehta J.L., Chen J., Hermonat P.L., Romeo F., Novelli G. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc. Res. 2006, 69:36-45.
4. Dunn S., Vohra R.S., Murphy J.E., Homer-Vanniasinkam S., Walker J.H., Ponnambalam S. The lectin-like oxidized low-density-lipoprotein receptor: a pro-inflammatory factor in vascular disease. Biochem. J. 2008, 409:349-355.
5. Mitra S., Deshmukh A., Sachdeva R., Lu J., Mehta J.L. Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy. Am. J. Med. Sci. 2011, 342:135-142.
6. Zelensky A.N., Gready J.E. The C-type lectin-like domain superfamily. FEBS J. 2005, 272:6179-6217.
7. Park H., Adsit F.G., Boyington J.C. The 1.4angstrom crystal structure of the human oxidized low density lipoprotein receptor LOX-1. J. Biol. Chem. 2005, 280:13593-13599.
8. Ohki I., Ishigaki T., Oyama T., Matsunaga S., Xie Q., Ohnishi-Kameyama M., Murata T., Tsuchiya D., Machida S., Morikawa K., Tate S. Crystal structure of human lectin-like, oxidized low-density lipoprotein receptor 1 ligand binding domain and its ligand recognition mode to OxLDL. Structure 2005, 13:905-917.
9. Xie Q., Matsunaga S., Niimi S., Ogawa S., Tokuyasu K., Sakakibara Y., Machida S. Human lectin-like oxidized low-density lipoprotein receptor-1 functions as a dimer in living cells. DNA Cell Biol. 2004, 23:111-117.
10. Ohki I., Amida H., Yamada R., Sugihara M., Ishigaki T., Tate S. Surface plasmon resonance study on functional significance of clustered organization of lectin-like oxidized LDL receptor (LOX-1). Biochim. Biophys. Acta 1814, 2011:345-354.
11. Falconi M., Biocca S., Novelli G., Desideri A. Molecular dynamics simulation of human LOX-1 provides an explanation for the lack of OxLDL binding to the Trp150Ala mutant. BMC Struct. Biol. 2007, 7:73.
12. Nakano S., Sugihara M., Yamada R., Katayanagi K., Tate S. Structural implication for the impaired binding of W150A mutant LOX-1 to oxidized low density lipoprotein, OxLDL. Biochim. Biophys. Acta 1824, 2012:739-749.
13. Biocca S., Falconi M., Filesi I., Baldini F., Vecchione L., Mango R., Romeo F., Federici G., Desideri A., Novelli G. Functional analysis and molecular dynamics simulation of LOX-1 K167N polymorphism reveal alteration of receptor activity. PLoS One 2009, 4:e4648.
14. Francone O.L., Tu M., Royer L.J., Zhu J., Stevens K., Oleynek J.J., Lin Z., Shelley L., Sand T., Luo Y., Kane C.D. The hydrophobic tunnel present in LOX-1 is essential for oxidized LDL recognition and binding. J. Lipid Res. 2009, 50:546-555.
15. Trott O., Olson A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31:455-461.
16. DeLano W.L. The PyMOL Molecular Graphics System 2002, DeLano Scientific, San Carlos, CA, USA.
17. Seeliger D., de Groot B.L. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J. Comput. Aided Mol. Des. 2010, 24:417-422.
18. Biocca S., Filesi I., Mango R., Maggiore L., Baldini F., Vecchione L., Viola A., Citro G., Federici G., Romeo F., Novelli G. The splice variant LOXIN inhibits LOX-1 receptor function through hetero-oligomerization. J. Mol. Cell. Cardiol. 2008, 44:561-570.
19. Cardinale A., Filesi I., Vetrugno V., Pocchiari M., Sy M.S., Biocca S. Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc accumulation. J. Biol. Chem. 2005, 280:685-694.
20. Sattler W., Bone P., Stocker R. Isolation of human VLDL, LDL, HDL and two HDL subclasses in the TL-100 tabletop centrifuge using the TLA-100.4 rotor 1992, Technical Information, Beckman.
21. Gillotte K.L., Horkko S., Witztum J.L., Steinberg D. Oxidized phospholipids, linked to apolipoprotein B of oxidized LDL, are ligands for macrophage scavenger receptors. J. Lipid Res. 2000, 41:824-833.
22. Stephan Z.F., Yurachek E.C. Rapid fluorometric assay of LDL receptor activity by DiI-labeled LDL. J. Lipid Res. 1993, 34:325-330.
23. Matarazzo S., Quitadamo M.C., Mango R., Ciccone S., Novelli G., Biocca S. Cholesterol-lowering drugs inhibit lectin-like oxidized low-density lipoprotein-1 receptor function by membrane raft disruption. Mol. Pharmacol. 2012, 82:246-254.
24. Cao W., Calabro V., Root A., Yan G., Lam K., Olland S., Sanford J., Robak A., Zollner R., Lu Z., Ait-Zahra M., Agostinelli R., Tchistiakova L., Gill D., Harnish D., Paulsen J., Shih H.H. Oligomerization is required for the activity of recombinant soluble LOX-1. FEBS J. 2009, 276:4909-4920.
25. Matsunaga S., Xie Q., Kumano M., Niimi S., Sekizawa K., Sakakibara Y., Komba S., Machida S. Lectin-like oxidized low-density lipoprotein receptor (LOX-1) functions as an oligomer and oligomerization is dependent on receptor density. Exp. Cell Res. 2007, 313:1203-1214.